中国癌症防治杂志
中國癌癥防治雜誌
중국암증방치잡지
CHINESE JOURNAL OF ONCOLOGY PREVENTION AND TREATMENT
2009年
2期
142-144,147
,共4页
任培蓉%吴敬波%何丽佳%吴天革%张建文%尚昌玲
任培蓉%吳敬波%何麗佳%吳天革%張建文%尚昌玲
임배용%오경파%하려가%오천혁%장건문%상창령
鼻咽癌%5-FU%动脉化疗%最大耐受剂量
鼻嚥癌%5-FU%動脈化療%最大耐受劑量
비인암%5-FU%동맥화료%최대내수제량
Nasopharyngeal carcinoma%5-fluorouracil%Intra-arterial chemotherapy%Maximum tolerated dose
目的 研究5-FU经颞浅动脉120h持续化疗高T分期鼻咽癌的最大耐受剂量(MTD).方法 对29例病理确诊为鼻咽癌的初治高T分期(T3或T4)患者采用颞浅动脉插管化疗.化疗方案:5-FU+顺铂,观察5-FU持续120h动脉灌注化疗的不良反应以及最大的耐受剂量.5-FU的剂量分别为200、300、350、400、450、500mg/m2,120h持续动脉滴注;顺铂20mg,第1～5天动脉快速滴注;21d为1疗程,共2个疗程.结果 不良反应: 29例病人均出现口腔黏膜反应,其中Ⅰ度1例为200mg/m2组;Ⅱ度12例200mg/m2组中5例,300mg/m2组5例,350mg/m2组2例;Ⅲ度11例300mg/m2组中1例,350mg/m2组3例,400mg/m2组5例,450mg/m2组2例;Ⅳ度5例450mg/m2组中3例,500mg/m2组2例;5例出现局部疼痛,对症治疗后好转.29例病人出现的骨髓抑制、消化道反应以及肝肾功能损害均在Ⅰ度和Ⅱ度.疗后原发灶CR 2例,PR 25例,SD 2例;有效率(CR+PR)为93%.颈部淋巴结CR 1例,PR 16例,SD 0例,余12例患者颈淋巴结为阴性,有效率(CR+PR)为100%.结论 5-FU经颞浅动脉持续化疗高T分期鼻咽癌,患者耐受尚可,最大耐受剂量为350mg/m2.
目的 研究5-FU經顳淺動脈120h持續化療高T分期鼻嚥癌的最大耐受劑量(MTD).方法 對29例病理確診為鼻嚥癌的初治高T分期(T3或T4)患者採用顳淺動脈插管化療.化療方案:5-FU+順鉑,觀察5-FU持續120h動脈灌註化療的不良反應以及最大的耐受劑量.5-FU的劑量分彆為200、300、350、400、450、500mg/m2,120h持續動脈滴註;順鉑20mg,第1～5天動脈快速滴註;21d為1療程,共2箇療程.結果 不良反應: 29例病人均齣現口腔黏膜反應,其中Ⅰ度1例為200mg/m2組;Ⅱ度12例200mg/m2組中5例,300mg/m2組5例,350mg/m2組2例;Ⅲ度11例300mg/m2組中1例,350mg/m2組3例,400mg/m2組5例,450mg/m2組2例;Ⅳ度5例450mg/m2組中3例,500mg/m2組2例;5例齣現跼部疼痛,對癥治療後好轉.29例病人齣現的骨髓抑製、消化道反應以及肝腎功能損害均在Ⅰ度和Ⅱ度.療後原髮竈CR 2例,PR 25例,SD 2例;有效率(CR+PR)為93%.頸部淋巴結CR 1例,PR 16例,SD 0例,餘12例患者頸淋巴結為陰性,有效率(CR+PR)為100%.結論 5-FU經顳淺動脈持續化療高T分期鼻嚥癌,患者耐受尚可,最大耐受劑量為350mg/m2.
목적 연구5-FU경섭천동맥120h지속화료고T분기비인암적최대내수제량(MTD).방법 대29례병리학진위비인암적초치고T분기(T3혹T4)환자채용섭천동맥삽관화료.화료방안:5-FU+순박,관찰5-FU지속120h동맥관주화료적불량반응이급최대적내수제량.5-FU적제량분별위200、300、350、400、450、500mg/m2,120h지속동맥적주;순박20mg,제1～5천동맥쾌속적주;21d위1료정,공2개료정.결과 불량반응: 29례병인균출현구강점막반응,기중Ⅰ도1례위200mg/m2조;Ⅱ도12례200mg/m2조중5례,300mg/m2조5례,350mg/m2조2례;Ⅲ도11례300mg/m2조중1례,350mg/m2조3례,400mg/m2조5례,450mg/m2조2례;Ⅳ도5례450mg/m2조중3례,500mg/m2조2례;5례출현국부동통,대증치료후호전.29례병인출현적골수억제、소화도반응이급간신공능손해균재Ⅰ도화Ⅱ도.료후원발조CR 2례,PR 25례,SD 2례;유효솔(CR+PR)위93%.경부림파결CR 1례,PR 16례,SD 0례,여12례환자경림파결위음성,유효솔(CR+PR)위100%.결론 5-FU경섭천동맥지속화료고T분기비인암,환자내수상가,최대내수제량위350mg/m2.
Objective To determine the maximum tolerated dose of 5-Flouruorail (5-FU) via superficial temporal arterial infusion for the patients with T3/T4 nasopharyngeal carcinoma.Methods A total of 29 patients were enrolled in this study.They were treated with 5-FU plus Cisplatin.A chemotherapy cycle was designed as 21 days and all patients were treated for 2 cycles.5-FU was administrated by pump infusion for continuous 120-hour via superficial temporal arterial.The maximum tolerated dose of 5-FU was determined by testing increasing doses on different groups of patient until the highest dose with acceptable side effects was found.Cisplatin was infused via superficial temporal artery (20mg/m2/d,d1-5) for all the patients.Results 5-FU induced oral mucositis in all patients.Of the 29 patients,1 patient experienced grade I mucositis in group 200mg/m2; 12 patients experienced grade II mucositis which included 5 in group 200mg/m2,5 in group 300mg/m2 and 2 in group 350mg/ m2; 11 patients experienced grade III mucositis which included 1 in group 300mg/m2,3 in group 350mg/m2,5 in group 400mg/m2 and 2 in group 450mg/m2; 5 patients experienced grade IV mucositis which included 3 in group 450mg/m2 and 2 in group 500mg/m2.Five patients experienced oral mucosal pain.For the primary tumor,2 cases achieved complete remission (CR),25 achieved partial remission (PR) and 2 presented stable disease (SD),in which the overall response rate (CR+PR) was 93%.For the neck lymph nodes,the cases of CR,PR and SD were 1,16 and 0 respectively,the rest 12 were neck-node-negative,in which the CR+PR was 100%.Conclusion s Superficial temporal arterial infusion with 5-FU for T3/T4 nasopharyngeal carcinoma is well tolerated.The maximum tolerated dose of 5-FU is 350mg/m2.
